A Sit Down With Cancer

Slideshow

A doctor sits down with Cancer to gauge its feelings towards new immunotherapy agents, lower smoking rates, and the US obesity epidemic.

As we bid farewell to last year, let us note that several exciting advances in the treatment of cancer were approved in 2017. New immunotherapy agents with high response rates against recalcitrant tumors led some of us optimistic types to believe that for the first time we might have unearthed the secret to victory. I tried to remain cool and collected while daydreaming about the day when this vile disease is eradicated, but my enthusiasm got the best of me and, like a cheeky reporter, I went so far as to schedule an interview with Cancer, in order to gauge how sanguine it feels about the future. Like Porfiry Petrovitch, the magistrate in Crime and Punishment who questions the murderer Raskolnikov, I sat down with Cancer, ready to interrogate it under the klieg lights. Here are some excerpts from our conversation.Caption/concept by Craig R. Hildreth, MDArtwork by Jon Carter, cartertoons.com

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content